Sato Hitoshi, Umemura Ken, Yamamoto Tae, Sato Hiroshi
Department of Internal Medicine, South-Miyagi Medical Center Hospital, Ogawara, Japan.
Department of Gastroenterology, South-Miyagi Medical Center Hospital, Ogawara, Japan.
BMJ Case Rep. 2017 Feb 9;2017:bcr2016218346. doi: 10.1136/bcr-2016-218346.
Although renal impairment is a rare complication of ulcerative colitis (UC), interstitial nephritis can occur as an idiosyncratic reaction to 5-aminosalicylate (5-ASA) treatment for UC. Monozygotic twins developed UC at ages 49 and 51, and they were separately treated at different medical institutes. They did not know that they had the same disease and were treated with the same drug (5-ASA). During the course of 5-ASA treatment, renal impairment diagnosed as interstitial nephritis occurred in both. Granulocyte/monocyte adsorption was initiated, UC remission was achieved and renal function deterioration subsided in both. Drug or treatment responses may be concordant in monozygotic twins with UC. Careful review is important before treatment to avoid serious adverse events.
虽然肾功能损害是溃疡性结肠炎(UC)的一种罕见并发症,但间质性肾炎可能作为对UC的5-氨基水杨酸(5-ASA)治疗的特异反应而发生。一对同卵双胞胎分别在49岁和51岁时患上UC,并在不同的医疗机构接受治疗。他们不知道自己患了同一种疾病,且都接受了相同药物(5-ASA)的治疗。在5-ASA治疗过程中,两人均发生了被诊断为间质性肾炎的肾功能损害。启动了粒细胞/单核细胞吸附治疗后,两人的UC均得到缓解,肾功能恶化也有所减轻。患有UC的同卵双胞胎的药物或治疗反应可能是一致的。治疗前进行仔细评估对于避免严重不良事件很重要。